ClinicalTrials.gg
TerminatedNCT05494762Updated May 1, 2025

Safety, Pharmacokinetics, and Antitumor Activity of BGB-B167 Alone and in Combination With Tislelizumab (BGB-A317) in Participants With Advanced Solid Tumors

A Phase 1 interventional study of BGB-B167 and Tislelizumab in Solid Tumor, sponsored by BeiGene. Terminated at 8 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-01.

Sponsored by BeiGene · Phase 1, Interventional, and Treatment

Why this study was terminated
Sponsor decision

From the registry’s dates

  • Primary completion was Feb 2025, 1 year 8 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
55
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

This study will evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary antitumor activity of BGB-B167 monotherapy and in combination with tislelizumab (BGB-A317) in participants with select advanced solid tumors.

02

Conditions studied

  • Solid Tumor
03

In context

Lead sponsor

BeiGene is the lead sponsor of 125 studies on the registry; 2 are open to participants now.

Of its 55 completed or terminated interventional studies of FDA-regulated products, 32 (58%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 or older
  • Participants with or cytologically confirmed unresectable locally advanced or solid tumors previously treated with standard systemic therapy or for whom treatment is not available, not tolerated, or refused, or not expected to provide significant clinical benefit or be tolerated in the medical judgement of the investigator
  • (ECOG) Performance Status ≤ 1
  • Adequate organ function as indicated by laboratory values during screening or ≤ 7 days before the first dose of study drug(s)

Exclusion criteria

Exclusion Criteria:

  • Active or uncontrolled, untreated
  • Active diseases or history of autoimmune diseases that may relapse
  • Any ≤ 3 years before the first dose of study drug(s) except for the specific cancer under investigation in this study and any locally recurring cancer that has been treated with curative intent
  • History of severe reactions to other monoclonal antibody products or their
  • Women who are pregnant or are breastfeeding

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
55 participants (actual)

Study arms

  • Experimental
    Phase 1a: Dose Escalation

    Part A: Increasing dose levels of BGB-B167 monotherapy; Part B: Increasing dose levels of BGB-B167 in combination with tislelizumab (BGB-A317)

    Drug: BGB-B167 · Drug: Tislelizumab

  • Experimental
    Phase 1b: Dose Expansion

    BGB-B167 alone or in combination with tislelizumab (BGB-A317)

    Drug: BGB-B167 · Drug: Tislelizumab

Interventions

  • DrugBGB-B167

    Intravenous administration

  • Intravenous administration

    Also known as: BGB-A317

06

What researchers measure

Primary outcomes

  1. Phase 1a: Number of Participants Experiencing Adverse Events (AEs)

    Time frame: Up to approximately 3 years

  2. Phase 1a: Number of Participants Experiencing Serious Adverse Events (SAEs)

    Time frame: Up to approximately 3 years

  3. Phase 1a: Number of Participants Experiencing AEs Meeting Protocol-defined Dose-limiting Toxicity (DLT) Criteria

    Time frame: Up to approximately 3 years

  4. Phase 1a: Maximum tolerated dose (MTD)

    MTD is defined as the highest tolerated dose with the target toxicity rate of 30%

    Time frame: Up to approximately 3 years

  5. Phase 1a: Recommended Phase 2 doses (RP2Ds)

    RP2Ds of BGB-B167 alone or in combination with tislelizumab will be determined based on a biologically effective dose

    Time frame: Up to 90 days after the last dose of study drug(s); up to approximately 3 years

  6. Phase 1b: Objective Response Rate (ORR)

    ORR is defined as the percentage of participants who had confirmed complete response (CR) or partial response (PR) as determined by investigators per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1

    Time frame: Up to approximately 3 years

Secondary outcomes

  1. Phase 1a: ORR

    ORR is defined as the percentage of participants who had confirmed complete response (CR) or partial response (PR) as determined by investigators per RECIST v1.1

    Time frame: Up to approximately 3 years

  2. Phase 1a and 1b: Duration of Response (DOR)

    DOR is defined as the time from the first determination of a confirmed objective response until the first documentation of progression or death due to any cause, whichever occurs first, as determined by investigators per RECIST v1.1

    Time frame: Up to approximately 3 years

  3. Phase 1a and 1b: Disease Control Rate (DCR)

    DCR is defined as the percentage of participants with best overall response (BOR) of confirmed CR, PR, or stable disease, as determined by investigators per RECIST v1.1

    Time frame: Up to approximately 3 years

  4. Phase 1a and 1b: Clinical Benefit Rate (CBR)

    CBR is defined as the percentage of patients with best overall response of confirmed CR, PR, or stable disease lasting ≥ 24 weeks, as determined by investigators per RECIST v1.1

    Time frame: Up to approximately 3 years

  5. Phase 1b: Progression-free Survival (PFS)

    PFS is defined as the time from the date of the first administration of study drug to the date of the first documentation of disease progression or death due to any cause, whichever occurs first, as determined by investigators per RECIST v1.1

    Time frame: Up to approximately 3 years

  6. Phase 1a and 1b: Serum Concentration of Tislelizumab

    Time frame: Up to approximately 3 years

  7. Phase 1a and 1b: Maximum observed serum concentration (Cmax) of BGB-B167

    Time frame: Up to approximately 3 years

  8. Phase 1a and 1b: Minimum observed serum concentration (Cmin) of BGB-B167

    Time frame: Up to approximately 3 years

  9. Phase 1a and 1b: Time to reach maximum observed serum concentration (Tmax) of BGB-B167

    Time frame: Up to approximately 3 years

  10. Phase 1a and 1b: Elimination half life (t1/2) of BGB-B167

    Time frame: Up to approximately 3 years

  11. Phase 1a and 1b: Area under the concentration-time curve in 1 dosing interval (AUCtau) of BGB-B167

    Time frame: Up to approximately 3 years

  12. Phase 1a and 1b: Total body clearance (CL) of BGB-B167

    Time frame: Up to approximately 3 years

  13. Phase 1a and 1b: Volume of distribution at steady state (Vss) of BGB-B167

    Time frame: Up to approximately 3 years

  14. Phase 1b: Number of Participants with AEs or SAEs

    Time frame: Up to approximately 3 years

  15. Phase 1a and 1b: Number of Participants with Antidrug Antibodies (ADAs)

    Time frame: Up to approximately 3 years

07

Study locations

8 sites
  • City of Hope National Medical Center
    Duarte, California 91010-3012, United States
  • Yale University, Yale Cancer Center
    New Haven, Connecticut 06520-8028, United States
  • Tennessee Oncology, Pllc Nashville
    Nashville, Tennessee 37203-1619, United States
  • Blacktown Cancer and Haematology Centre
    Blacktown, New South Wales 2148, Australia
  • Icon Cancer Centre Kurralta Park
    Kurralta Park, South Australia 5037, Australia
  • Monash Health
    Clayton, Victoria 3168, Australia
  • Peter Maccallum Cancer Centre
    Melbourne, Victoria 3000, Australia
  • The Alfred Hospital
    Melbourne, Victoria 3004, Australia
08

References and documents

Individual participant data

Plan to share: Yes — BeiGene shares data on completed studies responsibly and provides qualified scientific and medical researchers access to data and supporting documentation for clinical trials in dossiers for medicines and indications after submission and approval in the United States, China, and Europe. Clinical trials supporting subsequent local approvals, new indications, or combination products are eligible for sharing once corresponding regulatory approvals are achieved. BeiGene shares data only when permitted by applicable data privacy and security laws and regulations, when it is feasible to do so without compromising the privacy of study participants, and other considerations. Qualified researchers with appropriate competencies who are engaged in novel scientific research may submit a request for participant-level data with a research proposal for BeiGene review. Research teams must include a biostatistician and sign a Data Sharing Agreement prior to receiving access to clinical trial data.

Supporting information: Study protocol, Statistical analysis plan, Clinical study report

Time frame: See plan description

Access criteria: See plan description

Data sharing details ↗ · beigene.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2022 to primary completion in Feb 2025, 29 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 8, 2022
First posted
Aug 10, 2022
StartActual
Aug 25, 2022
Primary completionActual
Feb 24, 2025
CompletionActual
Feb 24, 2025
Last update
May 1, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 1, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05494762
Lead sponsor
BeiGene
Responsible party
Sponsor
First posted
Aug 10, 2022
Start date
Aug 25, 2022
Primary completion
Feb 24, 2025
Completion
Feb 24, 2025
Last update
May 1, 2025

Study contacts

Study Director
study director · BeiGene

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Apr 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Tislelizumab

Start the discussion